Novozymes A/S (NVZMY) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Novozymes A/S is expected to report quarterly results on May 14, with analysts projecting EPS of $0.816 and revenue of $1.323 billion; in its last reported quarter the company posted $0.51 EPS (missing the $0.82 consensus) and $1.31 billion in revenue.
• The stock carries a market cap of $25.4 billion and a PE ratio of 41.4, while the company reported a net margin of 14.22% and return on equity of 6.57%; the shares have a 52‑week range of $49.90–$75.99.
• Analyst sentiment is mixed—recent notes include a "strong-buy" upgrade and a "strong sell" cut—yet MarketBeat shows a consensus rating of Moderate Buy.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) is expected to issue its resultson Thursday, May 14th. Analysts expect the company to announce earnings of $0.8160 per share and revenue of $1.3230 billion for the quarter.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.31). The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.32 billion. Novozymes A/S had a return on equity of 6.57% and a net margin of 14.22%. On average, analysts expect Novozymes A/S to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Novozymes A/S Price Performance

Shares of OTCMKTS NVZMY opened at $61.27 on Thursday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.44 and a current ratio of 0.72. The company has a market cap of $25.40 billion, a PE ratio of 41.40, a P/E/G ratio of 1.17 and a beta of 0.98. The business has a 50-day simple moving average of $58.31 and a two-hundred day simple moving average of $61.13. Novozymes A/S has a fifty-two week low of $49.90 and a fifty-two week high of $75.99.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NVZMY. Rothschild & Co Redburn upgraded Novozymes A/S to a "strong-buy" rating in a research note on Friday, March 27th. Zacks Research cut Novozymes A/S from a "hold" rating to a "strong sell" rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy".

Novozymes A/S Company Profile

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company's product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.